Integrated Positron Emission Tomography - Computed Tomography (PET-CT) In Patients With Pancreatic Cancer

Study Overview

Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer

In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed. After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available. In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.

Compared to dynamic phase pancreatic CT, integrated PET-CT will be evaluated for sensitivity, specificity and accuracy of diagnosing and staging pancreatic cancer while the gold standard for pancratic cancer is operative specimen. If the operation can't be performed, EUS-FNA of the pancreatic mass or lymph node and additional imaging modality will be preferred to laparotomy.

Pancreatic Cancer

2008-0623

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2009-04-20	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2009-04-20
First Submitted that Met QC Criteria 2009-04-20	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2009-04-21
First Posted (ESTIMATED) 2009-04-21	Results First Posted N/A	Last Verified 2009-04

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Staging of pancreatic cancer		6 months after study start

Secondary Outcome Measures	Measure Description	Time Frame
Diagnosis of pancreatic cancer		6 months after study start

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Pancreatic mass suspicious of pancreatic cancer
No comorbidity, expected life expectancy less than 6 months
Consent this study in letter

Refuse diagnostic and staging work-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record